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OBJECTIVE—It is believed that an organism remains normo-
glycemic despite an increase in the -cell mass because of
decreased insulin production by -cells on a per-cell basis.
However, some transgenic mouse models with -cell hyperplasia
suggest that insulin production remains excessive and that
normoglycemia is maintained by insulin resistance.
METHODS—Here, we investigated the effect of an increased
-cell mass on glycemia and insulin resistance by grafting excess
normal islets in normoglycemic mice, as well as using targeted
PLAG1 expression in -cells, which leads to -cell expansion.
RESULTS—In both models, fasting plasma insulin levels were
increased, even though animals were normoglycemic. After an
intraperitoneal glucose tolerance test, plasma insulin levels in-
creased, which was associated with improved glucose clearing.
Under these conditions, normoglycemia is maintained by hepatic
insulin resistance as demonstrated by hyperinsulinemic euglyce-
mic clamp experiments.
CONCLUSIONS—In conclusion, we demonstrate that when
excess -cells are grafted, insulin production on a per -cell basis
is not sufficiently decreased, leading to hyperinsulinemia and
hepatic insulin resistance. This observation might be important
for the design of stem cell-based islet replacement therapies.
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Patients with type 1 diabetes produce very little orno insulin because of autoimmune destruction ofthe insulin-producing -cells. Several decadesago, it was shown that transplantation of isoge-
neic islets to replace -cells in diabetic rats could restore
normoglycemia (1). This has led to whole-pancreas or islet
transplantation to treat patients with type 1 diabetes (2).
One of the major hurdles for the routine use of this therapy
is the scarcity of transplantable islets. This forms the basis
for many studies that evaluate different methods to gener-
ate large numbers of -cells in vitro. In this context, stem
cells of both embryonic and adult origin offer interesting
perspectives (3).
It has been well established that successful islet trans-
plantation requires that sufficient islets are grafted and
survive to induce normoglycemia. However, what is not
known is the effect of grafting excess -cells on glucose
homeostasis. Only a single study has tested the effect of
grafting 300 C57BL/6 islets in normoglycemic mice, dem-
onstrating no effect on glucose metabolism (4). Normogly-
cemia, despite an increased -cell mass, may be achieved
by a decrease in insulin secretion on a per -cell basis (5).
Alternatively, the insulin secretion may remain elevated in
normoglycemic animals because of decreased insulin sen-
sitivity, documented in some, but not all, animal models in
which the -cell mass was increased by forced expression
of specific transgenes (6).
Here, we used two different mouse models to address
the mechanism underlying normoglycemia in animals with
a very large -cell mass: 1) mice in which the exogenous
-cell mass is increased by grafting 1,000 syngeneic islets
under the kidney capsule; and 2) mice in which the
endogenous -cell mass is increased by targeted overex-
pression of the human Pleomorphic Adenoma Gene 1
(PLAG1) in -cells.
PLAG1 is a developmentally-regulated zinc-finger tran-
scription factor (7,8). PLAG1 overexpression has been
linked to tumorigenesis in humans (9–14). Forced expres-
sion of PLAG1 in a tissue-specific manner in mice causes
formation of pleomorphic adenomas of the salivary glands
(15,16), adenomyoepitheliomatous lesions of the mam-
mary glands (17), and cavernous angiomatosis (18). Be-
cause PLAG1 overexpression leads to increased cell
proliferation, we hypothesized that targeted overexpres-
sion of PLAG1 in -cells might result in increased -cell
proliferation and might, as such, be a good method to
generate mice with an increased endogenous -cell mass.
Using both models, we clearly demonstrate that normo-
glycemia is maintained in mice that display persistent
hyperinsulinemia by the development of hepatic insulin
resistance.
RESEARCH DESIGN AND METHODS
FVB and C57BL/6 mice were purchased from Charles Rivers (Belgium) and
Janvier (France), respectively. The generation and genotyping of the PLAG1
transgenic mouse strain has been reported previously (15). To target PLAG1
expression to the -cells, PLAG1 transgenic mice were crossed with homozy-
gous RIP-Cre transgenic mice (a gift from Pedro Herrera, Switzerland), and
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backcrossed in a FVB background (19). This resulted in double-transgenic
PLAG1//RIP-Cre/ offspring mice, designated as P1-RIPCre mice.
Detection of PLAG1 expression by immunofluorescence. We stained
5-m cryostat sections using standard procedures, using a primary rat anti-HA
antibody (DAKO, Glostrup, Denmark) diluted 1/100 for 1 h at room tempera-
ture and the Alexa Fluor 546 goat anti-rat secondary antibody (Invitrogen,
Merelbeke, Belgium) in a dilution of 1/500 with Hoechst 33258 diluted 1/2,000
for 30 min at room temperature.
Immunohistochemical analysis of the pancreata. Pancreata were re-
moved, fixed overnight in 4% formaldehyde, and embedded in paraffin. For
each pancreas, six different sections separated by 200 m were selected for
histologic analysis. Paraffin sections (5 m) were stained with hematoxylin
and eosin. In addition, paraffin sections were stained with either a guinea pig
anti-insulin antibody (DAKO) diluted 1/2, a rabbit anti-glucagon antibody
(DAKO) diluted 1/1,500, or rabbit anti-somatostatin antibody (DAKO) diluted
1/750. As secondary antibodies, rabbit anti-guinea pig IgG coupled to peroxi-
dase (DAKO) diluted 1/200 or the anti-rabbit Envision kit (DAKO) were
used.
Morphometric analysis of -cell mass. Pancreata obtained from 20-week-
old P1-RIPCre and RIP-Cre mice, were stained for insulin on six sections of
each pancreas separated by 200 m. The total -cell surface area (mm2), that
is, the surface area of insulin positive cells, was determined with Zeiss
Axiovision software (Micro Imaging, Heidelberg, Germany). The percentage
of -cell surface area in the pancreas was calculated as (surface area of all
insulin-positive cells in one section/the total surface area of the section) 
100. The -cell mass was calculated by multiplying the pancreas weight by the
percentage of -cell surface area.
Determination of total pancreatic insulin content. Pancreata from P1-
RIPCre and RIP-Cre mice at different time points after birth were homoge-
nized in 5 ml of acidic ethanol (75% ethanol, 0.12M HCl), sonicated for 3 min,
incubated overnight at 20°C, and centrifuged at 4,000 rpm. The supernatant
fractions were collected for analysis of insulin content with the high range rat
insulin ELISA kit (Mercodia, Uppsala, Sweden).
Quantification of -cell proliferation. Three 5 m cryostat sections
separated by 200 m from pancreata of five 20-week-old P1-RIPCre and
RIP-Cre mice were stained with a mixture of a monoclonal mouse anti-insulin
antibody (Sigma, Bornem, Belgium) diluted 1/1,000 and a rat anti-Ki67
antibody (DAKO) diluted 1/50 for 1 h at room temperature. Subsequently,
sections were incubated with a mixture of Alexa Fluor 488 goat anti-mouse
and Alexa Fluor 546 goat anti-rat antibodies (Invitrogen), each diluted 1/500,
with Hoechst 33258 diluted 1/2,000 for 30 min at room temperature. -cell
proliferation was quantified as (the number of insulin/Ki67 cells of the 3
sections/total number of insulin cells per section)  100. At least 2,000
insulin-positive cells were counted per mouse.
Islet isolation and transplantation. Islets of 10- to 12-week-old male FVB
or C57BL/6 mice were isolated using previously published isolation proce-
dures (20).
Next, 10- to 12-week-old male isogeneic recipient mice were anesthetized
by intraperitoneal injection of 100 g ketamine and 10 g xylazine/gr body
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FIG. 1. Glucose homeostasis and glucose tolerance test (GTT) in mice transplanted with 1,000 islets. A: A quantity of 1,000 syngeneic islets were
grafted under the kidney capsule of FVB mice, and blood glycemia levels were followed for 2 months (full line). The dashed line represents blood
glucose levels of sham-operated littermate mice in function of time. At least 7 mice were included in both groups. Results are represented as
mean  SEM. *P < 0.05; **P < 0.005. B and C: GTT tests were performed on 11- to 13-week-old FVB mice transplanted with 1,000 islets 1 week
before the GTT (full line) and on sham-operated littermate mice (dashed line). The mice were starved for 16 h and injected with 1 mg/g glucose.
Blood samples were obtained at the indicated times, and plasma insulin (B) and blood glucose (C) levels measured. Data are shown as mean 
SEM. *P < 0.05; **P < 0.005. At least 15 mice were included per group. D: FVB mice grafted with 1,000 islets were nephrectomized 82 days after
transplantation, and an intraperitoneal GTT was performed 1 week later. Blood glucose levels of nephrectomized FVB mice initially transplanted
with 1,000 islets (full line) and nephrectomized sham-operated littermate mice (dashed line) are represented as mean  SEM. Four mice were
included per group. E: The total insulin content of the graft did not decrease between 1 day and 2 months after transplantation in C57BL/6 mice
transplanted with 1,000 islets. F: Two months after transplantation, the total endogenous pancreatic insulin content was significantly higher in
sham-operated littermate mice compared with C57BL/6 mice transplanted with 1,000 islets.
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weight. We transplanted 1,000 fresh islets under the left kidney capsule.
Sham-operated littermate mice were used as controls.
Nonfasting blood glucose levels and body weight of recipient and sham-
operated mice were measured daily during the first week and weekly
afterwards using a Contour glucose meter (Bayer, Diegem, Belgium).
Glucose tolerance tests and measurement of plasma insulin and gluca-
gon levels. Glucose (1 mg/g body weight) was administered in mice fasted for
16 h via intraperitoneal injection. Blood was drawn from the tail vein at 0, 30,
60, 90, 120, and 150 min after injection, and blood glucose levels measured
with a Contour glucometer.
Blood samples were collected in heparin-coated capillaries (Analis, Suar-
le´e´, Belgium) before and 30 and 120 min after glucose injection, and plasma
was prepared by centrifugation for 10 min at 1,000g.
Plasma insulin and glucagon levels were measured in 30 and 100 l of
plasma with the Mercodia ultra sensitive mouse insulin ELISA and the
Gentaur glucagon EIA (Kampenhout, Belgium).
Western blotting. After 16 h of starvation, P1-RIPCre and RIP-Cremice were
injected intraperitoneally with 1U/kg of insulin and killed 10 min later. The
liver lysates were analyzed by Western blot analysis using Akt (#4,691),
phosphoAkt(Ser473) (#4,060), and phosphoAkt(Thr308) (#2,965) antibodies
(Cell Signaling Technologies, Leiden, the Netherlands).
Homeostasis model assessment of insulin resistance test. A measure of
insulin resistance, the homeostasis model assessment of insulin resistance,
was calculated as fasting insulin (U/ml) fasting glucose (mmol/l)/22.5 (21).
Hyperinsulinemic euglycemic clamp study. The hyperinsulinemic euglyce-
mic clamp study was performed as published previously (22–24). In short, a
continuous infusion of D-3H glucose, 0.3 Ci/kg/min, (Perkin Elmer) was
started, and blood samples (60 l) were taken after 50 and 60 min of tracer
infusion to determine basal glucose, insulin, and free fatty acids (FFA). The
hyperinsulinemic study started with a bolus (100 mU/kg or 150 mU/kg for
P1-RIPCre and RIP-Cre mice, Actrapid, Novo Nordisk, Bagsvaerd, Denmark)
followed by continuous infusion of insulin (5 mU/h or 7.5 mU/h for RIP-Cre
and P1-RIPCre mice) and D-3H glucose (0.3 Ci/kg/min). A variable infusion of
12.5% D-glucose (in PBS) solution was adjusted to maintain euglycemia 70, 80,
and 90 min (steady state) after the start of the hyperinsulinemic period. Blood
samples (60 l) were taken for determination of plasma D-3H glucose, insulin,
and FFA concentrations.
For determination of plasma D-3H glucose, plasma was deproteinized with
20% trichloroacetic acid, dried to remove 3H2O, resuspended in demiwater,
and counted with scintillation fluid (Ultima Gold, Packard, Meridien, CT).
Plasma glucose, insulin, and FFA levels were determined using commer-
cially available kits (Instruchemie, Crystal Chemical and Wako Pure Chemical
Industries, respectively).
Under steady state conditions for plasma glucose concentrations, the rate
of glucose disposal equals the rate of glucose appearance. The glucose
disposal rate was calculated as the ratio of the infusion rate of D-3H glucose
(dpm/min) and the steady state plasma D-3H glucose specific activity (dpm/
mg/kg glucose). The hepatic glucose production was calculated as the
difference between the rate of glucose disposal and the infusion rate of
exogenous D-glucose.
Statistical analysis. Where appropriate, results are expressed as means 
SEM. Statistical analysis was performed by unpaired Student t test, where P
0.05 was considered significant.
RESULTS
Transplantation of exogenous islets results in hyper-
insulinemia. To formally test whether an organism re-
mains normoglycemic despite an increase in the -cell
mass, we transplanted 1,000 syngeneic islets under the
kidney capsule of normoglycemic FVB mice and evaluated
glycemia and insulin levels for 2 months afterward. The
glucose levels of mice transplanted with 1,000 islets de-
creased significantly for 2 days after transplantation com-
pared with sham-operated mice, but all animals were
normoglycemic from day 3 onwards (Fig. 1A). However,
plasma insulin levels in animals grafted with 1,000 islets
were 1.8-fold increased compared with sham-operated
mice, 1 week and 2 months after transplantation (ad
libitum fed: 1.93 0.27 g/l in sham-operated mice; 3.38
0.64 g/l in mice transplanted with 1,000 islets; starved
mice: 0.16  0.02 g/l in sham-operated mice; and 0.30 
0.05 g/l in mice transplanted with 1,000 islets). The basal
plasma glucagon level in starved FVB mice transplanted
with 1,000 islets (520  45 pg/ml) was also significantly
increased compared with sham-operated mice (300  7
pg/ml). After intraperitoneal glucose tolerance test (GTT),
insulin levels in mice transplanted with 1,000 islets rose to
significantly higher levels compared with sham-operated
mice (Fig. 1B), which was associated with a significantly
greater ability to dispose of glucose in mice grafted with
A 
B 
C 
pCAGGS PGK Neo-stop
RIP-Cre
+
PLAG1-HA
PLAG1-HApCAGGS
FIG. 2. Generation of PLAG1 transgenic mice. A: Schematic overview of the construct used to generate the PLAG1 transgenic founder line. After
crossing the PLAG1 transgenic founder line with RIP-Cre mice, the neomycin stop cassette becomes excised in -cells. This leads to expression
of PLAG1 in -cells. B and C: Immunofluorescent staining using an antibody against hemaglutinin clearly demonstrates the expression of the
PLAG1 transgene in -cells of 20-week-old P1-RIPCre mice (B), but not in littermate RIP-Cre mice (C).
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islets compared with sham-treated mice (Fig. 1C). Mice
were nephrectomized 82 days after transplantation, and an
intraperitoneal GTT was performed 1 week later. There
were no differences in the glucose levels of nephrecto-
mized mice initially transplanted with 1,000 islets and
sham-operated mice (Fig. 1D), indicating that differences
in mice harboring excess islets were caused by the trans-
planted islets.
These observations are independent of the genetic back-
ground of the mice, as C57BL/6 mice responded in a
similar way to the increased islet cell mass as FVB mice
(these data can be found in supplementary Fig. 1, available
in an online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-1446/DC1). The total insulin con-
tent of the graft remained unaltered 1 day and 2 months
after grafting 1,000 islets in C57BL/6 mice. (Fig. 1E) and was
85% of the total pancreatic insulin content. In contrast to
sham-operated C57BL/6 mice, in which the endogenous
pancreatic insulin content increased with age, the pancreatic
insulin content of C57BL/6 mice transplanted with 1,000
islets did not increase with time (Fig. 1F).
RIP-Cre-mediated overexpression of PLAG1 in
-cells results in an endogenous increase of the -cell
mass. To confirm that mice with an increased -cell mass
remain normoglycemic, a PLAG1 transgenic mouse strain
with -cell hyperplasia was developed (15) (schematically
represented in Fig. 2A). PLAG1 transgenic mice were
crossed with homozygous RIP-Cre transgenic mice (19) to
target stop-cassette excision and subsequent PLAG1 ex-
pression activation to the -cells. Such crossing resulted in
RIP-Cre//PLAG1/, RIP-Cre//PLAG1/ offspring
mice, designated P1-RIPCre and RIP-Cre mice, respec-
tively. Pancreata of P1-RIPCre mice expressed the trans-
gene as shown by immunofluorescence using an anti-HA
tag antibody in the nuclei of most -cells (Fig. 2B),
whereas no expression of the transgene could be detected
in the pancreata of littermate RIP-Cre mice (Fig. 2C).
Histologic analysis of 12-week- to 1-year-old male and
female mice revealed that targeted expression of PLAG1
in the -cells resulted in islet hyperplasia in P1-RIPCre
mice compared with littermate RIP-Cre mice. The -cell
mass was 1.9 times increased in 20-week-old male P1-
RIPCre compared with RIP-Cre mice (Fig. 3A). The pan-
creatic weight of 9-, 15- and 35-week-old P1-RIPCre mice
was also significantly increased compared with those of
littermate RIP-Cre mice (supplementary Fig. 2A). In con-
trast, the total body weight was similar (supplementary
Fig. 2B).
The islet cell distribution of P1-RIPCre mice was mildly
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FIG. 3. Quantification of -cell hyperplasia. A: The -cell mass of 20-week-old P1-RIPCre mice (black bar) is significantly increased compared with
those of littermate RIP-Cre mice (gray bar). Results are represented as mean  SEM. Five mice were analyzed per group. B: The total pancreatic
insulin content of P1-RIPCre mice (full line) was significantly increased compared with those of littermate RIP-Cre mice (dashed line) at
different time points after birth. C and D: The total pancreatic glucagon (C) and somatostatin (D) content of P1-RIPCre mice was similar to those
of littermate RIP-Cre mice at different time points after birth. Results are represented as mean  SEM. *P < 0.05; **P < 0.005. At least 10 mice
were included for each group at each time point.
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disturbed as demonstrated by immunostaining for insulin,
glucagon, and somatostatin. In contrast to islets of control
RIP-Cre mice in which the non--cells are located at the
periphery of the islets (Fig. 4A–C), some islets of P1-
RIPCre mice had non--cells randomly distributed
throughout the islet (Fig. 4 D–F).
In P1-RIPCre mice, the total pancreatic insulin content
was significantly increased in 6-, 9-, 15-, and 35-week-old
mice compared with littermate RIP-Cre mice (Fig. 3B),
indicating that the islet hyperplasia is present early after
birth. The total pancreatic somatostatin and glucagon
content was not increased in P1-RIPCre mice compared
with littermate RIP-Cre mice, consistent with the specific
expression of PLAG1 in -cells, and not in 	-cells and

-cells of P1-RIPCre mice (Fig. 3C and D).
Increased proliferation contributes to the islet hy-
perplasia in P1-RIPCre mice. The islet/-cell hyperpla-
sia observed in P1-RIPCre mice could be caused by
increased proliferation and/or decreased apoptosis of
PLAG1-overexpressing -cells. To determine -cell prolif-
eration in vivo, pancreata from 20-week-old male P1-
RIPCre and RIP-Cre mice were stained with antibodies
against insulin and Ki67, and the percentage of proliferat-
ing -cells was determined. In islets of RIP-Cre mice,
almost no proliferating -cells were detected (Fig. 5A),
whereas in islets of P1-RIPCre mice, proliferating -cells
were easily detected (Fig. 5B). The percentage of Ki67/
insulin cells in P1-RIPCre mice was 3.2-fold increased
compared with littermate RIP-Cre mice (Fig. 5C). Hence,
increased proliferation is at least one of the mechanisms
causing islet -cell hyperplasia in P1-RIPCre mice.
P1-RIPCre mice exhibit increased -cell mass, hyper-
insulinemia, and normoglycemia. Like FVB and C57/
BL/6 mice transplanted with 1,000 islets, P1-RIPCre mice
remained normoglycemic (Fig. 6A). Nevertheless, the
basal plasma insulin levels of 12-week-old and 35-week-old
starved P1-RIPCre mice were significantly increased (data
not shown). Similarly, the basal plasma C-peptide levels of
35-week-old P1-RIPCre mice were also significantly in-
creased compared with littermate RIP-Cre mice, pointing
toward an increased insulin secretion in these mice (Fig.
6B). In contrast, the basal plasma glucagon and somatosta-
tin levels were not altered in P1-RIPCre mice compared
with RIP-Cre mice (Fig. 6B). Like FVB mice transplanted
with 1,000 islets, P1-RIPCre mice showed an increased
ability to dispose injected glucose after GTT (Fig. 6C), and
accordingly, the plasma insulin levels were significantly
increased during GTT (Fig. 6D). Together, these data
suggest that P1-RIPCre mice that have an endogenous
increase in -cell mass respond in a similar way to the
increased -cell mass as mice in which the -cell mass has
been increased by islet transplantation.
Mice with an increased -cell mass become insulin
resistant. Because mice in which the -cell mass is
expanded by transplantation of excess islets or by forced
expression of PLAG1 in -cells have persistently elevated
insulin levels under starved or ad libitum fed conditions,
we hypothesized that normoglycemia may be maintained
because of insulin resistance. To evaluate this hypothesis,
we examined mice using the homeostasis model assess-
ment of insulin resistance (HOMA-IR). HOMA-IR was 80,
130, and 60% increased in FVB/C57BL/6 mice transplanted
with 1,000 islets and in P1-RIPCre compared with control
littermates, respectively. To confirm that P1-RIPCre mice
develop insulin resistance, insulin-activated Akt phosphor-
ylation was measured in liver lysates of P1-RIPCre and
RIP-Cre mice. As expected, acute insulin treatment (1
unit/kg) induced Akt phosphorylation in both groups.
However, insulin-activated Akt phosphorylation was re-
duced in P1-RIPCre mice compared with littermate RIP-
Cre mice, indicating that P1-RIPCre mice develop insulin
resistance (Fig. 6E).
A B C 
D E F 
FIG. 4. Islet cell distribution in P1-RIPCre mice. Stainings for insulin (A and D), glucagon (B and E), and somatostatin (C and F) on
representative sections of the pancreas of a 2-month-old RIP-Cre (A–C) and P1-RIPCre (D–F) mouse show that the islet cell distribution of
P1-RIPCre mice is slightly disturbed, with non--cells in the center of the islets.
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To conclusively demonstrate that mice with an in-
creased -cell mass in the two models become insulin
resistant, hyperinsulinemic euglycemic clamp experi-
ments were performed. For FVB mice, hyperinsulinemia
(3.50  0.46 g/l in mice transplanted with 1,000 islets vs.
3.57  0.38 g/l in wild-type mice) and euglycemia (Fig.
7C) were maintained during 5-mU/h insulin infusions,
whereas for P1-RIPCre and RIP-Cre mice, hyperinsulin-
emia (7.90 3.4 g/l vs. 3.86 0.21 g/l, respectively) and
euglycemia (Fig. 7D) were maintained during 7.5-mU/h
insulin infusions. A higher insulin infusion concentration
was used in this group because RIP-Cremice responded to
a lesser extent to the insulin infusion compared with
wild-type FVB mice, and they are, as such, slightly insulin
resistant. In FVB mice, glucose infusion rates were 55%
lower in mice transplanted with 1,000 islets than controls
(Fig. 7A), and, similarly, glucose infusion rates were 85%
lower in P1-RIPCre mice compared with controls (Fig.
7B). The glucose disposal rates were similar for FVB mice
transplanted with 1,000 islets compared with sham-oper-
ated littermates as well as for P1-RIPCre mice compared
with RIP-Cre mice under basal (Fig. 7G) and hyperinsu-
linemic (Fig. 7H) conditions. This indicates that the pe-
ripheral tissues remain insulin sensitive. The basal hepatic
glucose production was similar for FVB mice transplanted
with 1,000 islets compared with control littermates and for
P1-RIPCre mice compared with RIP-Cre mice (Fig. 7I).
Nevertheless, mice with an increased -cell mass develop
hepatic insulin resistance, as indicated by increased he-
patic glucose production during hyperinsulinemia in FVB
mice transplanted with 1,000 islets compared with control
FVB mice, as well as in P1-RIPCre mice compared with
RIP-Cre mice (Fig. 7J). The fat tissue of the mice did not
develop insulin resistance as no differences in insulin-medi-
ated inhibition of FFA release were observed during the
clamp in both groups (Fig. 7K and L). In conclusion, the
above data indicate that mice with an increased -cell mass
in the two models remained normoglycemic, despite being
hyperinsulinemic, because of hepatic insulin resistance.
DISCUSSION
Islet transplantation has been one of the reliable sources
of -cells to treat diabetic patients (2). However, several
obstacles still remain for a widespread application of this
method, such as the scarcity of islets for transplantation.
When more abundant sources of -cell–like cells become
available—for instance, if they are derived from stem
cells—it might be important to evaluate what happens if
too many -cells are transplanted. To investigate this
further, we generated a mouse model with an endogenous
increase of the -cell mass via PLAG1 overexpression in
the -cells and, more importantly, we transplanted normo-
glycemic mice with excess islets.
Several mouse models with islet hyperplasia have been
generated. Depending on the transgene used, the impact of
the -cell hyperplasia on glucose homeostasis appears to
differ. For instance, cyclin D1 (5) and Cdk4- (25) mediated
-cell hyperplasia results in normoglycemia and normal
insulin levels. Although this was not formally addressed,
these data would be consistent with the notion that
normoglycemia is preserved despite massive expansion of
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the -cell mass because production of insulin on a per cell
basis is reduced. By contrast, Igf2-mediated -cell hyper-
plasia results in elevated plasma insulin levels associated
with insulin resistance and ultimately development of type
2 diabetes (26). Finally, Akt1 (6,27) or Wnt- (28) mediated
-cell hyperplasia leads to hyperinsulinemia and normo-
glycemia, but without development of type 2 diabetes. We
also found that PLAG1-mediated excess of -cells leads to
hyperinsulinemic normoglycemia. Hence, under certain
circumstances, excess -cells lead to insulin resistance,
thereby maintaining normoglycemia.
As all these studies, including the PLAG1-mediated
hyperplasia of -cells described here, are performed in
mice overexpressing different transgenes in the -cell
compartment, it is possible that the unopposed increase in
-cells, but not 
- and 	-cells, is responsible for the
phenotype and might contribute to the impaired ability to
reduce insulin secretion on a per-cell basis. Furthermore,
it is not known whether mice that overexpress transgenes
in the -cell compartment are excessively producing “nor-
mal” -cells in terms of glucose sensing, fuel metabolism,
and insulin secretion dynamics.
Whether excess “normal” -cells, such as after graft-
ing stem cell-derived islets, will have a similar effect on
glucose metabolism is not known. In fact, once it
becomes possible to generate endocrine pancreatic
cells from stem cells suitable for transplantation, such
cells would not be genetically manipulated, and it is
likely that mixtures of -, 
-, and 	-cells, similar to those
found in normal islets, would be generated and would
be grafted. For these reasons, it was important to mimic
transplantation of excess and genetically unmanipu-
lated islets containing normal numbers of -, 
-, and
	-cells, and to evaluate insulin production in these
animals. We therefore transplanted a large excess of
normal islets in normoglycemic mice. This excludes the
possibility that effects seen on glucose and insulin
homeostasis are caused by the presence of a transgene
in endocrine pancreatic cells, which may influence the
function of the -cells. In mice transplanted with intact
islets, there is an increase in all endocrine cells, which
may mimic the transplantation of -cell containing stem
cell progeny. Indeed, we found that plasma glucagon
levels were elevated in animals grafted with excess
islets, but not in animals with PLAG1-induced islet
hyperplasia. Despite concomitant elevation in plasma
glucagon level, grafting 1,000 islets in syngeneic normo-
glycemic mice led to similar changes in glucose and
insulin homeostasis, as was observed in mice with
PLAG1-mediated islet hyperplasia.
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After grafting 1,000 islets in normoglycemic mice, recipient
mice were hypoglycemic for the initial 2 to 3 days after
surgery. It is possible that islet cell death immediately after
transplantation is responsible for increased insulin levels and
hence hypoglycemia. It is also possible that it requires several
days before insulin production and sensitivity homeostasis is
established in the setting of excess islets.
Previous studies demonstrated that after transplantation
of exogenous islets in normoglycemic mice, the transplanted
-cell mass decreased without significantly affecting the
endogenous -cell mass. These authors hypothesized that
recipient mice remained normoglycemic because of the
decrease in the transplanted -cell mass (4). In our study, a
similar plasticity of the -cell mass was observed. In contrast
to the previous study, in mice transplanted with 1,000 islets,
the endogenous -cell mass decreased, whereas the insulin
content of the graft did not decrease for up to 2 months after
transplantation. The decrease of the endogenous -cell mass
could not prevent the development of hyperinsulinemia in
transplanted mice. We clearly demonstrate that insulin secre-
tion from the combination of endogenous pancreas and
grafted islets remains elevated for at least 2 months after
transplantation. Despite the elevated basal plasma insulin
levels in mice transplanted with 1,000 islets, mice did not
display hypoglycemia because of the development of hepatic
insulin resistance, as demonstrated by hyperinsulinemic eu-
glycemic clamp experiments. This is consistent with what
has been shown for several published models of transgenic
islet hyperplasia (6) and for mice described here, in which
the endogenous -cell mass is increased by forced expres-
sion of PLAG1 in the -cells. After grafting cells under the
kidney capsule, insulin is released into the systemic circula-
tion which has already been described to lead to hepatic
insulin resistance (29). In contrast, islets transplanted in
humans are infused into the portal vein and release insulin
directly into the portal vein. We demonstrate that similar
insulin resistance occurs in the PLAG1 transgenic mouse
model where excess insulin and C-peptide are released in the
portal tract, as when islets are grafted under the kidney
capsule. When more abundant sources of islet cells become
available—for instance after differentiation of stem cells into
-cell-like cells—they will likely not be grafted in the liver,
but in a more accessible location, such as under the skin.
Here they will also release insulin in the systemic circulation
and might, as such, lead to hepatic insulin resistance as well.
Although our studies were only performed in mice and still
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of FVB mice transplanted with 1,000 islets (full line) and sham-operated littermate mice (dashed line). At time 0 min, an insulin infusion rate of
5 mU/h was started. B: Dynamics of the glucose infusion rates during hyperinsulinemic clamps of P1-RIPCre (full line) and RIP-Cre littermate
mice (dashed line). At time 0 min, an insulin infusion rate of 7.5 mU/h was started. C: Sequential blood glucose levels during hyperinsulinemic
clamps of FVB mice transplanted with 1,000 islets (full line) and sham-operated littermate mice (dashed line). An insulin infusion rate of 5 mU/h
was started at time point 10 min. D: Sequential blood during hyperinsulinemic clamps of P1-RIPCre (full line) and RIP-Cre littermate mice
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insulin infusion of P1-RIPCre mice (black bars) and RIP-Cre mice (gray bars) are given. G: Basal whole-body glucose disposal. H: Insulin-
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clamp. K: Basal plasma FFA. L: Plasma FFA during clamp. Data are represented as mean  SEM. *P < 0.05; **P < 0.005.
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need to be further validated in humans, the results suggest
that physicians will need to avoid grafting an excess numbers
of -cell–like cells, as this might lead to hyperinsulinemic
normoglycemia with concomitant insulin resistance.
It has been well established that insulin resistance in the
setting of obesity leads to increased -cell mass in mice
and humans (30). To our knowledge, this is the first report
that demonstrates the reverse may hold true; in the face of
an increased -cell mass, hepatic insulin resistance oc-
curs. These results should be kept in mind when designing
stem cell-based islet replacement therapies.
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